Study Summary
This trial is testing whether a new drug, VERU-111, can help treat patients with metastatic prostate cancer that has gotten worse despite other treatments.
- Metastatic Castration Resistant Prostate Cancer
- Androgen-Resistant Prostate Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 360 days
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Active control alternative androgen receptor targeting agent
1 of 2
Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a d...
1 of 2
Active Control
Experimental Treatment
245 Total Participants · 2 Treatment Groups
Primary Treatment: VERU-111 · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 100 · Male Participants · 17 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How does VERU-111 compare to other cancer treatments in terms of risk?
"VERU-111 is a Phase 3 trial medication, meaning that while there is some efficacy data supporting its use, there are multiple rounds of safety data. Because of this our team has given it a score of 3 in terms of safety." - Anonymous Online Contributor
Are there any spots still available in this trial for new patients?
"That is correct, the website clinicaltrials.gov has information indicating that this trial is looking for more participants. The exact number of patients they are trying to enroll is 245 individuals, and there are 52 different hospitals or clinics where the trial is taking place." - Anonymous Online Contributor
What are the most common maladies that doctors use VERU-111 to address?
"VERU-111 is an effective treatment for three different types of prostate cancer: non-metastatic, castration, and non-mestatatic castrate-resistant." - Anonymous Online Contributor
Are there any restrictions for patients who want to participate in this research?
"This study is looking for 245 men, aged 18 to 100, who currently have castration-resistant prostatic cancer. In addition to meeting the age criteria, participants must also: provide informed consent, be able to communicate effectively with study personnel, have histological or cytologic proof of adenocarcinoma of the prostate (not small cell carcinoma or neuroendocrine pathology), have radiographic evidence of metastatic disease at baseline by CT scan or MRI and bone scan, with confirmation of measurable disease by RECIST 1.1 and/or identifiable discrete bone metastases by PCWG3, know that they have castration" - Anonymous Online Contributor
Does this research trial allow for participants who are over thirty years of age?
"The age range for eligible participants in this clinical trial is 18 to 100 years old." - Anonymous Online Contributor
Yes, can you tell us about the previous research on VERU-111?
"VERU-111 was first studied in 2005 at the Rosemere Cancer Centre.193 clinical trials have been completed since then, with 223 additional trials currently underway. The majority of these ongoing studies are taking place in Merriam, Kansas." - Anonymous Online Contributor
What is the total number of participants in this research project?
"Veru Inc., the sponsor of this study, needs to enroll 245 eligible patients from a variety of clinical trial sites. Two examples of these participating locations are MidAmerica Cancer Care in Merriam, Kansas and Boca Raton Clinical Research (BRCR) Global USA in Plantation, Florida." - Anonymous Online Contributor
Could you please tell me how many research facilities are conducting this experiment?
"Currently, patients can enroll at MidAmerica Cancer Care in Merriam, Kansas; Boca Raton Clinical Research (BRCR) Global USA in Plantation, Florida; Centers for Advanced Urology, LLP MidLantic Urology in Bala-Cynwyd, Pennsylvania; and 52 other locations." - Anonymous Online Contributor